CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02401048
NCT02401048Phase 2Completed
CompareCT.gov

A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas

Pharmacyclics LLC.·interventional·Posted Mar 27, 2015·Updated Jun 27, 2019

In Brief

A Phase 2 clinical trial evaluating Ibrutinib and MEDI4736 for Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Completed, enrolled 61 participants across 11 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-Cell Lymphoma, Follicular Lymphoma
CountriesUnited States
CollaboratorsAstraZeneca, Janssen Research & Development, LLC

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 27, 2015
Enrollment StartMay 1, 2015
Primary CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.3 years ago

Interventions

Ibrutinibdrug

MEDI4736drug